en
Scientific article
English

A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin

Published inClinical endocrinology, vol. 86, no. 1, p. 128-133
Publication date2016
Abstract

Valproic acid (VA) is a histone deacetylase (HDAC) inhibitor that has antiproliferative effects on several types of cancer, including thyroid cancer. In addition, VA has been reported to upregulate the sodium-iodine symporter in thyroid cancer cells and increases radioiodine uptake in preclinical studies. The aim of this study was to assess the antiproliferative effects of VA and to evaluate if VA can increase the radioiodine uptake in patients with advanced, radioiodine-negative thyroid cancer.

Citation (ISO format)
NILUBOL, Naris et al. A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin. In: Clinical endocrinology, 2016, vol. 86, n° 1, p. 128–133. doi: 10.1111/cen.13154
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0300-0664
429views
0downloads

Technical informations

Creation11/22/2016 9:30:00 AM
First validation11/22/2016 9:30:00 AM
Update time03/15/2023 1:08:51 AM
Status update03/15/2023 1:08:51 AM
Last indexation01/16/2024 10:42:38 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack